NasdaqGS:DYNBiotechs
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate
Dyne Therapeutics recently announced that Japan’s Ministry of Health, Labour and Welfare granted Orphan Drug designation to zeleciment basivarsen for treating myotonic dystrophy type 1, complementing ongoing Phase 1/2 ACHIEVE trial work.
This latest designation, adding to similar statuses in the U.S. and Europe, strengthens the global regulatory support behind Dyne’s DM1 program.
Next, we’ll explore how this new Japanese Orphan Drug designation for zeleciment basivarsen shapes Dyne...